Finkelstein Thompson LLP is investigating potential claims on behalf of shareholders of King Pharmaceuticals Inc. (“King” or the “Company”) (NYSE: KG) concerning the sale of the Company to Pfizer Inc. for $14.25 in cash for each share of common stock owned in a transaction valued at approximately $3.6 billion. The investigation is focused on the potential unfairness of the deal price to King shareholders, the process by which the Board of Directors considered the transaction, and potential conflicts of interests among King Board members. According to Yahoo! Finance, at least one analyst has set a target price of $15.00 for King stock. If you are interested in discussing your rights as a King shareholder, or have information relating to this investigation, please contact Finkelstein Thompson's Washington, DC offices at (877) 337-1050 or by email at email@example.com. Finkelstein Thompson LLP has spent over three decades delivering outstanding representation to institutional and individual clients in financial litigation, and has been appointed as lead or co-lead counsel in dozens of shareholder class actions. Indeed, the firm has served in leadership roles in cases that have recovered over $1 billion for investors and consumers. To learn more about Finkelstein Thompson LLP, please visit our web site at www.finkelsteinthompson.com. Attorney advertising. Prior results do not guarantee similar outcomes.